Uterine artery embolisation or myomectomy for women with uterine fibroids wishing to avoid hysterectomy: a cost–utility analysis of the FEMME trial
Rattachement africain : gb. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVES: To assess the cost-effectiveness of uterine artery embolisation (UAE) and myomectomy for women with symptomatic uterine fibroids wishing to avoid hysterectomy. DESIGN: Economic evaluation alongside the FEMME randomised controlled trial. SETTING: 29 UK hospitals. POPULATION: Premenopausal women who had symptomatic uterine fibroids amenable to UAE or myomectomy wishing to avoid hysterectomy. 254 women were randomised to UAE (127) and myomectomy (127). METHODS: A within-trial cost-utility analysis was conducted from the perspective of the UK NHS. MAIN OUTCOME MEASURES: Quality-adjusted life years (QALYs) measured using the EuroQoL EQ-5D-3L, combined with costs to estimate cost-effectiveness over 2 and 4 years of follow-up. RESULTS: Over a 2-year time horizon, UAE was associated with higher mean costs (difference £645; 95% CI -1381 to 2580) and lower QALYs (difference -0.09; 95% CI -0.11 to -0.04) when compared with myomectomy. Similar results were observed over the 4-year time horizon. Thus, UAE was dominated by myomectomy. Results of the sensitivity analyses were consistent with the base case results for both years. Over 2 years, UAE was associated with higher costs (difference £456; 95% CI -1823 to 3164) and lower QALYs (difference -0.06; 95% CI -0.11 to -0.02). CONCLUSIONS: Myomectomy is a cost-effective option for the treatment of uterine fibroids. The differences in costs and QALYs are small. Women should be fully informed and have the option to choose between the two procedures. TWEETABLE ABSTRACT: Fully informed women with uterine fibroids should have a choice between uterine artery embolisation or myomectomy.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Uterine artery embolisation or myomectomy for women with uterine fibroids wishing to avoid hysterectomy: a cost–utility analysis of the FEMME trial
- Date Crossref
- 05/07/2021
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Glasgow Health Economics and Health Technology Assessment (HEHTA) Institute of Health & pays non établi dans la noticeUniversité ou école supérieure
-
Cancer Research UK Clinical Trials Unit pays non établi dans la noticeStructure de recherche
-
University of Birmingham Birmingham Clinical Trials Unit pays non établi dans la noticeUniversité ou école supérieure
-
University of Nottingham Nottingham Clinical Trials Unit pays non établi dans la noticeUniversité ou école supérieure
-
Whipps Cross University Hospital pays non établi dans la noticeÉtablissement de santé
-
St George's Hospital Department of Gynaecology pays non établi dans la noticeÉtablissement de santé
-
University of Oxford Department of Primary Care pays non établi dans la noticeUniversité ou école supérieure
-
School of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Department of Obstetrics and Gynaecology Whipps Cross Hospital London UK Department of Obstetrics and Gynaecology pays non établi dans la noticeÉtablissement de santé
Health Economics and Health Technology Assessment (HEHTA) Institute of Health & — University of Glasgow, Cancer Research UK Clinical Trials Unit et Birmingham Clinical Trials Unit — University of Birmingham, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.